Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19,667,509
-
Number of holders
-
253
-
Total 13F shares, excl. options
-
22,068,878
-
Shares change
-
-649,360
-
Total reported value, excl. options
-
$2,469,185,512
-
Value change
-
-$52,085,687
-
Put/Call ratio
-
464%
-
Number of buys
-
115
-
Number of sells
-
-140
-
Price
-
$111.85
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q2 2020
302 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q2 2020.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 253 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22,068,878 shares
.
Largest 10 shareholders include BlackRock Inc. (2,127,655 shares), JANUS HENDERSON GROUP PLC (1,604,974 shares), VANGUARD GROUP INC (1,486,603 shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1,486,504 shares), STATE STREET CORP (1,010,188 shares), WASATCH ADVISORS INC (971,423 shares), CARDINAL CAPITAL MANAGEMENT LLC /CT (868,385 shares), MACQUARIE GROUP LTD (742,053 shares), Conestoga Capital Advisors, LLC (672,768 shares), and VILLERE ST DENIS J & CO LLC (647,668 shares).
This table shows the top 253 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.